Adjuvants are substances used to enhance the efficacy of vaccines. They influence the magnitude and alter the quality of the adaptive immune response to vaccine antigens by amplifying or modulating different signals involved in the innate immune response. The majority of known adjuvants have been empirically identified. The limited immunogenicity of new vaccine antigens and the need for safer vaccines have increased the importance of identifying single, well-defined adjuvants with known cellular and molecular mechanisms for rational vaccine design. Depletion or functional inhibition of CD4 + CD25 + FoxP3 + regulatory T cells (Tregs) by molecular adjuvants has become an emergent approach in this field. Different successful results have been obtained for specific vaccines, but there are still unresolved issues such as the risk of autoimmune disease induction, the involvement of cells other than Tregs and optimization for different conditions. This work provides a comprehensive analysis of current approaches to inhibit Tregs with molecular adjuvants for vaccine improvement, highlights the progress being made, and describes ongoing challenges.
Introduction
A vaccine is a biological preparation that induces acquired immunity to a particular disease, providing protection (prophylactic vaccine) or aiding treatment (therapeutic vaccine). Vaccines typically have a basic composition that includes two principal components: one or more antigens derived from a causal agent, responsible for the specificity, and an adjuvant to enhance the immunogenicity and protective efficacy of the vaccine [1] .
Over several decades, studies of vaccines have evolved towards the search for well-characterized and highly-purified antigens, such as recombinant proteins and peptides; over the last several years, this search has included the introduction of defined, potent and safer adjuvants for a new generation of vaccines [2] . Aluminum salts were the first substances used as vaccine adjuvants, and they were the only approved adjuvants in preventive human vaccines for decades. However, owing to their relatively weak capacity to induce cellular immunity and an emerging debate regarding possible links between aluminum and certain severe post-vaccination reactions [3, 4] , the search for alternative adjuvants has become an area of intense investigation. For many years, the search for new adjuvants has been active but empirical, and as a consequence, a growing number of new substances with documented adjuvant activity have been reported in the literature. However, owing to safety concerns, very few adjuvants, such as MF59 and AS03, have been licensed for use in human vaccines [2, 5] . For this reason, there has been an increasing trend towards the rational design of vaccines using defined molecules with well-characterized cellular and molecular mechanisms of action. One of the current directions of this approach is the targeting of immune regulatory networks [6] .
Regulatory T cells (Tregs) are a heterogeneous subpopulation of T cells that modulate the quality and magnitude of immune responses. These cells play critical roles in the maintenance of immunological tolerance to self-antigens, avoiding autoimmune diseases, infection-induced tissue damage, allergies, transplant rejection and other dangers associated with inflammation [7] . Although Tregs can control excessive inflammation associated with cancer and infection, excessive suppression can also affect immune responses against certain tumors and microorganisms. Thus, balanced Treg function is essential in order to maintain immune homeostasis [8] .
Recent studies have revealed considerable heterogeneity and plasticity within Treg populations in different microenvironments [9, 10] . Their central role in immune regulation has stimulated an emerging interest in the design and development of new bioactive molecules targeting Tregs for the pharmacological management of immune-mediated diseases [11, 12] . Accordingly, numerous studies have focused on the role of Tregs in post-vaccination immune responses as a way to improve vaccine immunogenicity and effectiveness [13] [14] [15] .
This review summarizes the main strategies that are currently being evaluated to improve vaccines by Treg targeting with defined molecules (molecular adjuvants). Advances and ongoing challenges that remain to be resolved are critically analyzed.
Origin, development and function of regulatory T cells
T lymphocytes play a central role in cell-mediated immunity. They are called T cells due to their origin and maturation in the thymus. T helper cells (Th cells) are a type of T lymphocyte that helps the activity of other immune cells by releasing cytokines. These cells help or regulate the function of other immune cells. They aid the antibody production by B lymphocytes, are essential in the activation and growth of cytotoxic T cells (CTLs), and promote the activity of innate immune cells, such as the phagocytosis of neutrophils and macrophages and the cytotoxicity of natural killer cells. Th1 cells develop when a specific cellular-mediated immune response is required for the control of infections and tumors. Their main effector cytokine is IFN-␥. Th2 cells are effectors against extracellular parasites, including helminths. Their effector cytokines are IL-4, IL-5, IL-9, IL-10 and IL-13. Th17 cells are defined by their production of IL-17. They play an important role in pathogen clearance at mucosal surfaces, are effective against pathogenic fungi and are also involved in different inflammatory process [7, 8] .
The existence of T cells with a suppressive capacity was first proposed in 1970 [16] . CD25 was the first phenotypic marker identified for suppressive T cells, found several years later by Sakaguchi in mice [17] . Shortly thereafter, a CD4 + CD25 high T cell population with suppressive function was also identified in humans by several groups [18] [19] [20] [21] [22] . Simultaneously, mutations in the Foxp3 gene were identified as being responsible for an X-linked recessive inflammatory disease in Scurfy mice, which spontaneously develop severe autoimmune/inflammatory illnesses [23] . Furthermore, mutations in the human gene FOXP3, the ortholog of murine Foxp3, were found to be the cause of IPEX (immune dysregulation, polyendocrinopathy, enteropathy X-linked syndrome), a similar human autoimmune disease [24] [25] [26] . In 2003, several groups reported that FOXP3 is a key molecule essential for the development and function of Tregs; immediately thereafter, it became the main marker for Treg populations in mice [27] [28] [29] and humans [30, 31] .
The majority of human CD4 + CD25 high Tregs also express FOXP3, but in contrast to mice, human CD4 + CD25 − FOXP3 − T-cells and CD8 + CD25 − FOXP3 − T-cells also show a transient FOXP3 + CD25 + state during activation [32] . For this reason, the IL-7 receptor (CD127), which is downregulated during Treg maturation, is often used for their identification, and it is now accepted that CD4 + CD25 high CD127 low/− represents a more specific phenotype for human Treg identification [33] .
There are two main subsets of Tregs: natural Tregs (nTregs), which are thymus-derived, and induced, adaptive or peripheral Tregs (pTregs), which are derived from naive CD4 + T cells under a variety of conditions [34] . Characteristically, nTregs have epigenetic demethylation of the T regulatory cell-specific demethylation region (TSDR), a promoter region of Foxp3. Owing to this selective demethylation of TSDR, Foxp3 cannot be switched off; these cells and their progeny therefore cannot revert to effector T cells (Teffs). Neuropilin-1 (Nrp-1), a protein originally characterized based on its functions in the central nervous system, and Helios, an Ikaros transcription family member, are two important molecules involved in the suppressive activity of Tregs. These molecules were originally reported to be constitutively expressed at high levels on nTregs, and they are frequently used to distinguish between nTregs and pTregs [35] . However, it was recently found that high expression of Nrp-1 is not a specific characteristic of many nTregs, and low expression of Helios and Nrp-1 does not exclusively indicate pTregs cells. Thus, the reliability of Nrp-1 and Helios as markers discriminating between nTregs and pTregs, is now controversial [36] .
Following antigen presentation and in the presence of high concentrations of IL-2, nTregs express receptors for IFN␥ and IL-12 (Th1 cytokines) and are named first-order T suppressor cells (Ts1). If inflammation persists, Ts1 cells are further expanded to Th1-like Tregs that express both FOXP3 and Tbet (the Th1 transcription factor) and produce IFN␥ but not IL2 [37] .
pTregs arise from peripheral CD4 + CD25 − FOXP3 − T cells that are exposed to antigen in the presence of transforming growth factor-␤ (TGF␤) without IL-6 or IL-1␤. In this microenvironment, FOXP3 expression is triggered, but its expression is not stable, and the expression of ROR T (the transcription factor of Th17 cells) is inhibited. However, they have a CD4 + CD25 + phenotype and express other markers of nTregs, such as CTLA-4 and GITR [37] .
Other T cells acquire regulatory functions following antigenic stimulation in specific cytokine milieus. These cells include IL-10-secreting Tr1 cells, IL-35-secreting Tr35 cells, TGF␤-secreting T helper 3 (Th3) cells, certain CD4 − CD8 − T cells, CD8 + CD28 − T cells, NKT regulatory cells and T follicular regulatory cells [38, 39] . The more important Teff cells that are suppressed by Tregs are Th1, Th2, Th17 and CTLs.
Mechanisms of immunosuppression by Tregs
Treg-mediated suppression can be accomplished in two ways: by cell-cell contact or by means of soluble mediators and cytokines (paracrine signaling). Several mechanisms have been identified as involved in the immunosuppressive function of Tregs, including (1) inhibition by immunoregulatory cytokines such as TGF␤, IL-10, and IL-35; (2) cytolysis of effector cells by producing granzyme and perforin; (3) metabolic interruption, including inhibition of proliferative response via the IL-2 receptor, cAMP-mediated metabolic inhibition, and immunomodulation mediated by the A2 adenosine receptor; and (4) interactions with dendritic cells that modulates their function and maturation [40] . A thorough description of these mechanisms is provided in Table 1 .
Targeting Tregs in vaccination
Different studies have shown that depletion of Tregs prior to vaccination in murine models enhances the immune responses to certain vaccines, suggesting that Tregs can interfere with the generation of vaccine-induced immunity [41] [42] [43] [44] [45] . Over the last several years, two valuable models have been developed for the study of Tregs: transgenic DEREG mice (depletion of regulatory T cells), which express a fusion protein of the receptor for diphtheria toxin (DT) and enhanced green fluorescent protein (GFP) under the control of the Foxp3 locus [46] , and B6.Foxp3hCD2 mice, a transgenic mouse model containing a sequence coding for a GPI-linked human CD2-CD52 fusion protein in the 3 UTR of the X-linked Foxp3 gene such that all Foxp3-expressing cells co-express the fusion protein on their cell surface. In B6.Foxp3hCD2 mice, Treg depletion is achieved using ablative anti-human CD2 antibodies [47] . These mice allow selective depletion of total FOXP3 + Tregs without affecting CD25 + Teffs.
Though the role of Tregs in controlling vaccine immunogenicity remains to be fully determined, different approaches are being evaluated for achieving effective modulation of Treg activity post-vaccination. Several immunological characteristics of Tregs, such as their high expression of different markers (e.g., CTLA-4; CD25; CCR4, FOXP3), their active proliferative capacity, and their apoptosis-prone tendency, can be exploited to specifically control their functions [48] . In this way, different molecules are being evaluated to reduce the immunosuppressive effects of Tregs in prophylactic or therapeutic vaccination against different pathological conditions, including cancer and infectious diseases. These molecules, with well-defined molecular targets, can serve as molecular adjuvants enhancing vaccine immunogenicity ( Fig. 1 ). Other molecules, not discussed here, can elicit pharmacological Treg activation and may help control autoimmune diseases and allergies [13, 14, 49, 50] .
At least four distinct mechanisms have been described for molecular adjuvants targeting Tregs: 1) Depletion by direct killing of Tregs or reducing de novo generation via differentiation and expansion; 2) Inhibition of Treg function through immune checkpoint blockade; 3) Disrupting homing (migration) of Tregs to inflammatory sites; and 4) Exploiting T-cell plasticity to convert Tregs into IL-17-secreting T cells (Th17) [51] (Fig. 2) . The following sections will be devoted to analyzing each of the compounds that have demonstrated significant effects as molecular adjuvants by targeting Tregs.
Metronomic chemotherapy
Chemotherapy, which mainly destroys proliferating cells, may skew Tregs towards becoming Teffs [52] . Low doses (metronomic doses) of cyclophosphamide (CY) and other cytostatic agents have been extensively used to inhibit Tregs for vaccine improvement due to their low cost and wide availability [53, 54] . In 1974, Polak and Turk reported that CY reversed immune tolerance induced by two intravenous injections of dinitrobenzene sulfonic acid (DNBSO3) in a guinea pig-sensitization model through inhibition of a putative suppressor T-cell population [55] . Berd and collaborators subsequently demonstrated significant antitumor immune responses with regression of metastases after treatment with a melanoma cell vaccine preceded by CY treatment given in metronomic doses [56, 57] . Lutsiak and colleagues evaluated the function of Tregs isolated from untreated and CY-treated mice two and ten days after 2 mg of intraperitoneal CY treatment. CY-treated Tregs decreased the expression of GITR and Foxp3 and exhibited an increased susceptibility to apoptosis with significant impairment in their suppressive capacity, which returned by day 10 after treatment [58] . More recently, Heylmann and collaborators demonstrated that Tregs are more sensitive than CTLs and other T cells to mafosfamide, an active derivative of CY, which does not require metabolic activation. The high sensitivity of Tregs to mafosfamide resulted not only in enhanced induction of apoptosis but also in impaired Treg function, as demonstrated by a decline in the suppressor activity of Tregs in a co-culture model with Teffs and Helios + Tregs [59] . However, the clinical benefit achieved by CY-mediated depletion of Tregs as an immunomodulatory approach appears to be variable Granzymes can enter the effector T cells through a pore formed by perforin or by endocytosis to induce apoptosis.
Metabolic interruption High expression of CD25
Inhibition of proliferative responses of effector T cells by competition for IL-2. Adenosine CD39 and CD73 are ectoenzymes highly expressed on the surface of Treg cells. CD39 is the cell surface-localized prototypic member of the ecto-nucleoside triphosphate diphosphohydrolase (E-NTPDase) family, and it degrades ATP into AMP. Extracellular AMP is rapidly degraded into adenosine by CD73, known as ecto-5 -nucleotidase. The adenosine resulting from AMP hydrolysis binds to adenosine receptors (A1, A2a, A2b, and A3) present on many cell types, and these regulate multiple physiological responses, including anti-inflammatory effects.
Inhibition of dendritic cell maturation and function CTLA-4 CTLA-4, also known as CD152, is constitutively expressed in Tregs and induced in conventional T cells following activation. This molecule has a high affinity for dendritic cell-expressed CD80 and CD86; thus, the role of CTLA-4 is to regulate CD28-dependent T cell activation. CTLA-4-CD80/CD86 interaction induces catabolism of tryptophan by means of IDO. Tryptophan catabolism leads to the release of kynurenines, which are potent immune suppressors. Lymphocyte-activation gene 3 (LAG3, CD223)
LAG3 is a cell-surface molecular homologue of the CD4 receptor and is expressed in Tregs. LAG3 binds to MHC-II with higher affinity than CD4. The LAG3-MHC-II union induces a signaling cascade in dendritic cells that decreases the function of antigen capture. [60]. Sevko et al. reported that the myeloid-derived suppressor cells Gr1 + CD11b + (MDSCs) are strongly induced in the tumor microenvironment when Tregs are depleted, affecting the desired therapeutic response of low-dose CY. Tregs depletion increases the production of several inflammatory mediators, such as GMCSF, IL-1␤, IL-5, IL-10, IFN␥ and TNF␣, in the tumor microenvironment; all of these factors are involved in MDSC expansion and activation. MDSCs exhibited elevated immunosuppressive activity, including the inhibition of T-cell proliferation and nitric oxide (NO) production. In addition, MDSCs are able to stimulate Tregs, leading to proliferation, survival, and growth of the tumor cells [61] .
Other immunosuppressant drugs, including calcineurin inhibitors, cyclosporine (CsA), and tacrolimus (FK506), might also reduce Treg numbers and function depending on the doses utilized. Kawai reported that high-dose CsA abrogates Treg generation, whereas a lower dose (10 mg/kg) of CsA promoted Treg development [62] . On the other hand, mycophenolate mofetil and high doses of rapamycin facilitated the generation of regulatory cells by intratracheal delivery of alloantigens in mice, while low doses of rapamycin and FK506 did not interfere with the generation of Tregs [63] . Paclitaxel is another drug that has been used to improve vaccine immunogenicity. Chen et al. tested metronomic low doses of paclitaxel in combination with a chimeric DNA vaccine, CTGF/E7 (connective tissue growth factor linked to the tumor antigen human papillomavirus 16 E7), to treat existing tumors in mice. Paclitaxel enhanced the vaccine's potential to delay tumor growth and decreased metastatic dissemination in vivo better than CTGF/E7 DNA vaccination alone. According to the authors, metronomic therapy improved the effects of the vaccine by two mechanisms: depletion of Tregs and inhibition of tumor angiogenesis, rather than direct cytolytic effects [64] .
Monoclonal antibody targeting CD25
The human IL-2 receptor exists in three isoforms generated by different combinations of three different proteins; they are often referred to as alpha (IL-2R␣ or CD25), beta (IL-2R␤ or CD122), and gamma (IL-2R␥ or CD132). Improved vaccine immunogenicity can be achieved by Treg depletion with systemic anti-CD25 monoclonal antibody administration [65] . A murine model was developed in which C57BL/6 mice were vaccinated with dendritic cells (DCs) pulsed with or without peptides from the syngeneic C1498 myelomonocytic leukemic cell line. In this model, depletion of CD25 + T cells with anti-CD25 monoclonal antibody before DCbased vaccination allowed the generation of long-lived immune responses. Vaccinated mice that underwent Treg depletion were protected from subsequent re-challenge by C1498 cells, with an improved survival in comparison with mice that received vaccination alone [66] . Johnson et al. subsequently evaluated whether anti-CD25 treatment could favor effective antitumor immunity when administered immediately before cell-based vaccination. They observed that anti-CD25 antibodies induced murine neuroblastoma Neuro-2a rejection and elevated survival after challenge with a lethal dose of tumor cells, in association with improved vaccine antitumoral immunogenicity [67] .
In another preclinical study, the attenuation of Treg subsets concomitant with BCG vaccination showed a positive but limited impact on the protective capacity of this vaccine against infection with Mycobacterium tuberculosis [68] . However, PC61 mAb (anti-murine CD25 rat IgG1) administered in conjunction with CY reduced tumor progression in early-stage but not late-stage mouse models of pancreatic carcinoma immunized with an antitumor vaccine preparation [69] . Similarly, the treatment of mice with established disease in a murine melanoma model using PC61 and DC/tumor fusion enhanced vaccine immunogenicity and significantly reduced the numbers of pulmonary metastases [70] .
Daclizumab is a humanized anti-CD25 antibody built by total gene synthesis using oligonucleotides. This antibody is 90% human, retaining 10% of the original murine compartments in critical hypervariable segments for binding specificity. Daclizumab has been used in several human anticancer vaccine trials to enhance immune responses to tumor antigen vaccination. Studies with this product have shown long-lasting depletion of Tregs and enhanced CD8 and CD4 T cell immune responses without the development major autoimmune responses [71, 72] .
Denileukin diftitox (DAB389IL-2 or ONTAK ® ) is an immunotoxin that consists of an IL-2 fusion protein and the enzymatically active membrane-translocating domains of diphtheria toxin. After binding to CD25, Denileukin diftitox is internalized, and the released toxin is cytocidal for CD25 + T cells [73] . This compound can deplete Tregs, albeit transiently, with Treg nadirs persisting for less than 3 weeks, although it can also deplete various T subsets, including tumor antigen-specific CD8 + T cells [51] . Litzinger et al. evaluated the effects of denileukin diftitox in combination with a recombinant poxviral vaccine to enhance antigen-specific immune responses. Administration of the immunotoxin one day before vaccination enhanced antigen-specific T cell responses above levels induced by vaccination alone [71, 74] . Another report revealed the effects of denileukin diftitox before vaccination with tumor RNA-transfected dendritic cells. A reduction in circulating CD4 + CD25 + T cells with higher specific immune responses to vaccine in comparison with no denileukin diftitox treatment was observed [75] . In a pilot study, fifteen patients with carcinoembryonic antigen (CEA)-expressing malignancies received denileukin diftitox, given as a single dose or via repeated dosing, followed by immunization with DCs modified with the fowlpox vector rF-CEA(6D)-TRICOM. A T-cell response to CEA associated with Treg depletion was observed in the multiple-dose group but not in the single-dose group [76] . In contrast, Curiel et at. Tested the immune and clinical effects of Treg depletion using denileukin diftitox in phase 0/I and phase II epithelial ovarian carcinoma cancer trials. The treatment depleted Tregs without clinical benefit in advanced stages [77] . In another study, denileukin difitox was administered to patients with melanoma on a 5-day schedule. The study revealed a failure in Treg depletion, suggesting that a difference in dose or administration schedule may be important [78] . Recently, a randomized study failed to demon-strate an improvement in clinical outcomes with a single dose of denileukin diftitox in vaccinated patients suffering advanced melanoma, suggesting that continued investigation with this compound should be discouraged [79] .
Monoclonal antibody to CTLA-4
CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), also known as CD152, is a member of the immunoglobulin superfamily constitutively expressed in Tregs and induced in Teffs after activation. CTLA-4 is homologous to the T-cell co-stimulatory protein CD28, and both molecules bind to CD80 (B7-1) and CD86 (B7-2) on antigen-presenting cells. CTLA-4 functions as an immune checkpoint that downregulates the immune responses [80] . The first anti-CTLA-4 antibody was developed by James P. Allisonís group to treat patients with late-stage melanoma, prostate and experimental mammary carcinoma. They demonstrated that in vivo antibody-mediated blockade of CTLA-4 enhances antitumor immune responses of experimental vaccines [81] [82] [83] [84] . However, anti-CTLA-4 antibody treatment induced autoimmune responses when associated with antitumor vaccines [83] [84] [85] .
Ipilimumab is a monoclonal antibody that inhibits Tregs by blocking CTLA-4, thus activating the immune system; the Food and Drug Administration (FDA) approved it in 2011 as an adjuvant therapy for the treatment of advanced melanoma [86] . However, ipilimumab treatment causes severe immunological adverse reactions associated with T cell overstimulation in 10-20% of patients, including stomach pain, bloating, constipation or diarrhea, fever, rash, colitis, hypophysitis, hepatitis, pancreatitis, iridocyclitis, lymphadenopathy, neuropathy and other neurologic disorders, and nephritis [87] [88] [89] .
Anti-GITR
Glucocorticoid-induced TNFR-related protein (GITR), is a member of the tumor-necrosis-factor receptor (TNFR)-family; it is naturally expressed by Tregs but is also detected, at much smaller levels, on CD4 + and CD8 + effector T cells. The constitutive high level of expression of GITR in resting Treg cells unequivocally indicates the important role of this molecule in the modulation of the immune system. [90] . Agonistic antibodies to either GITR or GITR ligand cause both enhanced proliferation of Teffs and the simultaneous suppression of Treg activity [91] as well as protection or tumor regression in experimental models [92, 93] .
Agonist anti-GITR antibodies have been evaluated as potential tools for vaccine improvement, but autoimmune reactions were concomitantly observed [93] [94] [95] . However, dendritic cells transfected with RNA encoding the heavy and light chains of the anti-GITR mAb, to secrete anti-GITR antibodies, are effective adjuvants to DC-based tumor immunotherapy. Vaccination with anti-GITR-secreting DCs and tumor antigen-presenting DCs significantly enhanced antitumor immunity, comparable to levels seen with systemically delivered mAbs along with antigen-presenting DCs but without evidence of autoimmune effects [96, 97] .
Anti-OX40
OX40 (CD134) is another costimulatory molecule of the TNF receptor family. This immune checkpoint is constitutively expressed on Tregs and is transiently expressed on Teffs. OX40 signaling impairs the suppressive capacity of Tregs, presumably through direct inhibition of Foxp3 expression [98] . OX40 signaling also antagonizes TGF␤ and the conversion CD4 + CD25 − naive T Cells to inducible CD4 + CD25 + Tregs [99] . Anti-OX40 antibody treatment has divergent effects on Treg cells (increased and decreased survival, inhibition of Foxp3 expression). Studies using anti-OX40 antibodies suggest that antibody-dependent cell cytotoxicity (ADCC) is an important mechanism for killing cells that express OX40 at their surface, including Tregs [100] . One preclinical study showed that an agonistic anti-OX40 monoclonal antibody was able to inhibit the suppressive activity of Tregs [98] . Another study showed a significant inhibition of tumor growth after intratumoral injection of this antibody, which exhibited a dual role by inhibiting Treg suppression while enhancing Teff functions [101] . A recent critical review analyzed different studies using anti-OX40 antibody in cancer immunotherapy [100] .
OX40 ligands have shown adjuvant properties for improving anti-tumor and anti-infectious disease vaccines. OX40 ligand inclusion with BCG vaccination provided enhanced protection against aerosol and intravenous M. tuberculosis challenges when compared with BCG vaccination alone in a murine model [102] . More recently, a peptide vaccination strategy against melanoma was developed by combining synthetic peptides with toll-like receptor (TLR) agonists and OX40/CD40 co-stimulation. This vaccination strategy generated significant antitumor effects in a mouse model, and it was efficient in overcoming immune tolerance to a self-tumorassociated antigen [103] . Another study revealed that vaccination with a mixture of synthetic peptides of mouse cytomegalovirus and OX40 agonistic antibodies resulted in relevant antitumor responses mediated by CD4 + and CD8 + T cells. This response was higher when compared to those induced by the virus alone, and it was associated with a reduction in both viral titers and dissemination after viral challenge in mice [104] .
Modulation of the programed death-1 pathway
Programmed Cell Death Protein 1, also known as PD-1 or CD279, is a member of the CD28 superfamily. It is expressed by Tregs and other immune cells and acts to downregulate immune responses. This immune checkpoint enhances tolerance by suppressing T cell inflammatory activity through interaction with its ligands PD-L1 and PD-L2, leading to Treg activation [105] [106] [107] .
PD-1 pathway blockade is a successful strategy for vaccine potentiation. Pembrolizumab and Nivolumab are anti-PD-1 humanized antibodies approved by the FDA for use in cancer immunotherapy against several solid tumors, although several autoimmune reactions have been reported, as seen with other checkpoint inhibitors [108] [109] [110] . Despite the encouraging responses seen with the use of these antibodies, the majority of patients do not respond to PD-1/PD-L1 blockade, perhaps owing to the inability of tumors to stimulate a productive T cell response. For this reason, an effective vaccine that stimulates de novo highavidity CD4 and CD8 responses prior to checkpoint blockade could be a valuable alternative strategy for non-responsive patients. Recently, Xue et al. demonstrated that vaccination using a DNAbased strategy to induce high-avidity antitumor specific T cell responses combined with PD-1 blockade resulted in an 85% survival rate in an aggressive B16 melanoma model [111] . In other studies, the effects of antitumor vaccination were evaluated in association with either dual blockade of PD-1/CTLA-4 [112] or a combined CD27 agonist and PD-1 blockade. Combined CTLA-4/PD-1 blockade improved vaccine efficacy, but this combination was much less potent than the CD27 agonist/PD-1 blockade combination [113] .
Indoleamine 2,3-dioxygenase inhibitors
Indoleamine 2,3-dioxygenase (IDO) is an endogenous enzyme involved in immune regulation by suppressing T cell function. IDO catalyzes the degradation of tryptophan by the kynurenine pathway and is involved in the generation and activation of Tregs [114, 115] . IDO has been associated with reduced immunogenicity following vaccination with MVA85A, a modified vaccinia virus expressing antigen 85A from M. tuberculosis [116] . Blockade of Treg immune-inhibitory signals through inhibition of the IDO pathway is emerging as an important modality for cancer therapy, particularly for the development of antitumor vaccines. Several IDO inhibitors are being investigated in clinical trials with promising initial results, including INCB024360, indoximod, and NLG919 [117] [118] [119] .
Anti-LAG-3
Lymphocyte Activation Gene-3 (LAG-3) or CD223 is a CD4-related molecule that binds MHC class II and is expressed by nTregs upon activation. LAG-3 plays a role in suppression mediated by nTregs and iTregs. In addition, the expression of LAG-3 on naive CD4 + T cells significantly reduces their proliferative capacity and can confer regulatory functions independent of the FOXP3 pathway [120] [121] [122] . Tregs from LAG-3 −/− mice exhibit reduced regulatory activity, while antibodies to LAG-3 abolish the suppressive capacity of Tregs [120] .
In 1999, Prigent et al. transfected either human LAG-3 or mouse LAG-3 into three types of tumor cells (MCA 205, TS/A and RENCA) to evaluate their capacity to stimulate a tumor-specific immune response in vivo. LAG-3-transfected tumors either completely regressed or had their growth markedly reduced. In addition, mice were protected against re-challenge with parental tumor cells. The adjuvant effect of soluble LAG-3 was subsequently evaluated when co-administered with the MCA 205 cell line and the TS/A cell line. LAG-3 enhanced antitumor responses, and significant reductions in tumor growth were observed in both tumor models when compared with animals vaccinated with tumor cells alone [123] . Another study showed that vaccinated mice with particulate hepatitis B surface antigen or soluble ovalbumin (Ova) protein with soluble LAG-3, increased specific CTL responses, including a proliferative response of splenocytes with a greater Th1-but not Th2-type cytokine pattern. Moreover, vaccine formulation with LAG-3 induced higher titers of specific antibodies than in mice immunized without LAG-3 [124] . Other similar approaches using the soluble form of LAG-3 in different models have confirmed its utility as a new type of molecular adjuvant in vaccines [125, 126] .
CCR4 antagonists
C-C chemokine receptor type 4 (CD194) is a receptor for different chemokines, including both CCL22 and CCL17, chemotactic agents involved in Treg recruitment to inflammatory sites and tumors [127] . More than 85% of Tregs are CCR4 + , and CCR4 antagonists can be used as vaccine adjuvants to decrease local recruitment of Tregs at the site of immunization [128, 129] . This new generation of molecular adjuvants enhanced specific immune responses against different pathogens and experimental murine tumors when injected in combination with vaccine antigens [128] [129] [130] . The halflife of CCR4 antagonists is just 24 h, causing a transitory functional inhibition of Tregs. Their relatively short duration of action reduces the potential for autoimmune reactions when compared with the longer half-life (approximately 2-3 weeks) of monoclonal antibodies that are used to deplete Tregs or to inhibit their functions [131, 132] . However, recent clinical studies of Mogamulizumab, a humanized anti-CCR4 monoclonal antibody used for leukemia and lymphoma treatment, showed the development of graft-versushost disease (GVHD) and other severe adverse drug reactions in some patients. These findings suggest that patients receiving anti-CCR4 therapy should be carefully monitored for adverse events [133, 134] .
Anti-FOXP3
The FOXP3 transcription factor, the specific marker of Tregs, is regarded as a self-antigen. As FOXP3 is more specific for Tregs than CD25 and other molecules, anti-FOXP3 vaccination does not interfere with vaccine-induced protective immunity. Thus, inducing immune responses against FOXP3 Tregs appears to be a potential approach to decrease the frequency of Tregs and to enhance specific immune responses. However, FOXP3 is not expressed on the cell surface; consequently, it cannot be reached with antibodies in vivo.
Vaccination of mice with Foxp3 mRNA-transfected dendritic cells is capable of stimulating specific CTL production and selective depletion of Foxp3 + Tregs. This approach enhances vaccineinduced protective immunity similar to that of ␣CD25 antibody administration [135] . Mousavi et al. used a chimeric FOXP3-Fc(IgG) fusion construct/protein to effectively stimulate immune responses against Tregs. Their study revealed the efficiency of a Foxp3 DNAprime protein-boost strategy to decrease Tregs with significant superiority when compared to the Fc(IgG) fusion strategy. Treg depletion was also associated with higher FOXP3-specific CTL and Th1 responses in FOXP3-Fc vaccinated mice [136] . Gene silencing was used to block the expression of either Foxp3 or CTLA-4. This strategy improved the antitumor efficacy of a GM-CSF genetically modified tumor cell vaccine against B16 melanoma. Interestingly, the characteristic adverse effects of treatment with anti-CTLA-4 antibodies, i.e., depigmentation, diarrhea, or weight loss, were not observed [137] . However, a vaccine designed to eliminate polyclonal Treg cells in a permanent way could theoretically cause severe medium-or long-term immunological disturbances. Thus, further studies are necessary for definitive conclusions regarding the safety of these molecules as vaccine adjuvants.
Finally, a 15-mer synthetic peptide (P60) with the capacity to inhibit FOXP3 function was identified using phage-displayed peptide libraries. P60 enters the cells and reduces the ability of FOXP3 to suppress the transcription factors NF-kB and NFAT. In vitro, P60 inhibited murine and human-derived Tregs and elicited Teff stimulation. When evaluated in vivo, P60 improved the antiviral efficacy of a recombinant adenovirus vaccine, expressing the NS3 protein from hepatitis C virus. Moreover, protection was induced against CT26 tumor cell implantation in mice immunized with the cytotoxic T cell epitope AH1 derived from these cells. P60 did not cause toxic effects in adult mice, although in newborn mice, it induced a lymphoproliferative autoimmune syndrome similar to that observed in Scurfy mice [138] . Another peptide (FOXP3 393-403) generated by the same group also exhibited similar properties as P60 and showed antitumor efficacy in mice bearing Hepa129 or TC1 tumor cells when combined with sorafenib (a kinase inhibitor anticancer drug) or with an antitumor vaccine, respectively [139] . More recently, P60 was conjugated with a CD28-targeting aptamer to deliver the peptide to CD28-expressing cells. The efficacy and biodistribution of P60 was improved with this approach [140] .
These findings suggest that targeting FOXP3 with inhibitory peptides can provide a specific and simple protocol to enhance vaccination efficacy with reduced risk of autoimmunity, but the clinical applicability of these strategies still needs to be demonstrated.
Blockade of TGFP
17 is a short synthetic peptide that inhibits TGF␤1 and TGF␤2 and was created by the same group that developed the FOXP3 peptide inhibitors. This peptide inhibited the TGF␤1-dependent expression of collagen type I mRNA in the livers of mice orally challenged with carbon tetrachloride and blocked the inhibitory activity of TGF␤1 on the growth of Mv-1-Lu cells in vitro [141] .
Moreover, P17 inhibited Treg cells in vitro and improved the efficacy of vaccination in vivo. P17 inhibited tumor growth, reduced the number of CD4 + FOXP3 + T cells and augmented the proliferation of CD4 + T cells purified from OT-II transgenic mice adoptively transferred into C57BL/6 mice bearing EG.7-OVA tumors. Moreover, P17 blocked the induction of Ag-specific oral tolerance induced in vivo after intragastric supplementation of the OVA-secreting Lactococcus lactis (LL-OVA) in DO11.10 mice [142] . Another strategy for blockade of TGF␤ is antibody-mediated inhibition of TGF␤, which enhanced tumor vaccine efficacy and protection mediated by CD8 + T cells, although the adjuvant effects appear to be independent of Treg targeting [143] .
Listeriolysin O
In 2007, Nitcheu-Tefit et al. provided the first evidence that listeriolysin O (LLO) affects Treg function [144] . A remarkable level of protection against ovalbumin (OVA)-expressing tumor cells was observed in mice vaccinated with Escherichia coli expressing LLO and OVA (E. coli LLO/OVA) in comparison with mice vaccinated with E. coli expressing OVA alone (E. coli/OVA). In addition, Tregs from E. coli LLO/OVA-vaccinated animals were unable to suppress Teff proliferation. Subsequent studies showed that immunization with an E. coli-LLO vaccine carrying a cancer-relevant antigen (Wilms tumor antigen-1) inhibited Treg expansion and enhanced antitumor responses [145, 146] . The underlying mechanism related to the Treg inhibition by LLO remains to be elucidated.
Blockade of adenosine-mediated immune suppression
Extracellular ectonucleotidases CD39 and CD73 of Tregs produce adenosine (ADO) via catabolism of adenine nucleotides (ATP, ADP and AMP) [147] . ADO is a major mediator involved in Treg function due to its direct immunosuppressive effects via reduction of T-cell and natural killer (NK)-cell responses. ADO also contributes to reduced transendothelial migration of Teffs into tumors [148, 149] . Inhibition of CD39 with enzymatic inhibitors and adenosine receptor antagonists blocks Treg function. Different molecular structures, some of which have already been used in clinical studies for diverse indications, are being evaluated to block adenosinemediated immune suppression as a therapeutic alternative for different diseases and as a vaccine adjuvant [148, 150] . However, even though CD39, CD73, adenosine, and adenosine receptors act in synergy, they are not equal, and each represents a unique target with a singular profile. Thus, a thorough investigation of the expression and the role of each molecule is required for future clinical use in vaccines [149, 150] .
Anti-angiogenic molecules
Tregs make significant direct contributions to tumor angiogenesis [151] . Various studies have shown that angiogenesis inhibitors also inhibit various Treg-immunosuppressive networks [152] . Sunitinib, an inhibitor of tyrosine kinases involved in angiogenesis, causes depletion of Tregs, especially after the second cycle of therapy. Other tyrosine kinase inhibitors, such as imatinib mesylate, dasatinib, and temozolomide, can also deplete Tregs in association with an inhibitory effect on their function. Potential uses of these molecules as immunological adjuvants requires further study [52] .
Anti-folate receptor 4 antibodies
Anti-Folate Receptor 4 (FR4) was identified by Spiegelstein et al. in mice. This molecule is homologous to human FR-␦ [153] . FR4 is highly expressed in nTregs, and it plays an important role in the maintenance of Treg phenotypes [154, 155] . Several studies in murine tumor models have demonstrated the beneficial effects of modulating Treg function by anti-FR4 antibodies. Partial rejection of MethA and MCA fibrosarcomas, CT26 colon carcinomas, and RENCA renal carcinoma were observed after direct anti-FR4 antibody administration [154, 156] . Moreover, an enhanced antitumor response associated with modest protection against autologous B16m5T4 melanoma challenge was observed when anti-FR4 antibodies were administered after immunization with 5T4 oncofetal glycoprotein [157] . As anti-FR4 antibody treatment as a monotherapy can result in modest rejection of tumors, Liang et al., depleted Tregs as part of a combination therapy using an anti-FR4 antibody and GM-CSF-secreting tumor cell immunotherapy (GVAX) for treatment of melanoma-bearing animals. With this strategy, they showed that these two agents could function cooperatively to enhance the median survival time in this tumor model. In addition, triple combination of a blocking CTLA-4 antibody with GVAX and anti-FR4 treatment further enhanced overall survival and reduced growth of well-established melanomas [158] .
Nicotinamide adenine dinucleotide
Functional levels of nicotinamide adenine dinucleotide (NAD + ) are released during inflammation. This mediator participates in the regulation of T cell homeostasis, causing T cell death, principally of Tregs, a process that is known as NAD-induced cell death (NICD) [159, 160] . Endogenous NAD + influences survival, phenotype, and function of Tregs by an ART2/P2 × 7-dependent process [161] . Systemic administration of NAD + reduced Treg numbers and provoked significant anti-tumor immunity [161] . Recently, it was demonstrated that in addition to depletion of murine CD4 + CD25 high FOXP3 + Tregs, NAD + favors the conversion of Tregs into IL-17A-producing cells and promotes allograft survival by Treg-independent systemic IL-10 production [162] .
Toll-like receptor (TLR) modulation
TLR agonists have been widely used as adjuvants in coadministration with different types of antigens. In addition to their relevant role in activating the innate immune response, studies of the basic biology of TLR agonists suggest a role in modifying Treg functions. [163] . Exposure of Tregs to poli-G10, a TLR8 ligand, elicited improved antitumor immunity by abolishing their suppressive action on CD8 + T cells [164] . Another report showed that the synthetic bacterial lipoprotein BLP, a TLR1/TLR2 agonist, led to dose-dependent tumor regression and a long-lasting protective response against tumor challenge. This effect was associated with a reduced suppressive function of Tregs and enhanced cytotoxicity of tumor-specific CTLs in vitro and in vivo [165] . A recent study demonstrated the effects of the high mobility group box-1 protein 1 (HMGB1) and lipopolysaccharide (LPS) on TLR4 signaling in Tregs. Tregs treated with HMGB1 directly increased the expression of the pro-inflammatory cytokine IFN␥ and inhibited its suppressive function, whereas LPS treatment upregulated the expression of IL-1␤ and IL-10 and promoted their suppressive capacity. In both cases, the activation of the NF-B pathway was involved [166] . These findings suggest that immunomodulation through TLRs can induce either activation or reduction of Treg responses. Further studies are necessary to define the critical factors leading to each of these effects.
Anti-co-stimulatory receptor (ICOS) antibody
Inducible co-stimulator (ICOS) or CD278 is a member of the CD28/Cytotoxic T-lymphocyte Antigen-t4 (CTLA-4) family broadly and is expressed in activated CD4 + T cells and iTregs. ICOS is implicated in important Tregs functions, as ICOS + Tregs exhibit 
Risks versus benefits of Treg manipulation
Enhancement of adaptive immune responses by Treg modulation does not always correlate with improved disease outcomes and is often associated with undesired effects. Treg regulation involves highly complex mechanisms that are not yet well-defined [170] . Hence, all attempts of Treg modulation for disease treatment and prevention should be carefully evaluated. Fig. 3 depicts an overview of possible consequences of Treg manipulation. In the case of Treg targeting for vaccine improvement, the ideal response should be a transient Treg inhibition during the active phase of immunological induction to avoid overstimulation. A delay in Treg recovery by excessive or long-lasting depletion could disrupt immune tolerance, inducing inflammatory disorders and potential autoimmune processes [131] . This risk has been observed in mice as a consequence of Treg depletion, resulting in the appearance of localized autoimmune disease, such as skin depigmentation associated with tyrosinase-related protein 2 (180-188)-specific CTLs [83] . The incidence and spectrum of autoimmune diseases induced by Tregs depletion depends in part on the degree and duration of Treg depletion, the age of the host (the risk is greater in neonatal mice than in adult mice), the route of administration (systemic or local), and the genetic background of the host [171, 172] .
On the other hand, improper modulation inducing the opposite effect (Treg stimulation) can lead to the failure of vaccination and may cause unwanted effects due to immunosuppression. This potential effect can occur when the same receptors are used to inhibit or stimulate Tregs or with a nonspecific depletion by targeting common pathways, affecting both Tregs and Teffs. Certainly, Tregs and activated T cells share several features and receptors, which explains the weak selectivity of different immunomodulators for specific Treg inhibition [52, 171] . New strategies are currently being designed to inhibit Treg function rather than their deletion using combined checkpoint inhibition to improve vaccine efficacy and safety [52, 171, 173] .
Conclusions
Although Treg responses have rarely been evaluated during pharmacological studies of vaccine candidates, several studies in different models have provided convincing evidence that these cells can constrain the induction of effector T-cell responses induced by vaccination. In fact, depletion or inhibition of Tregs by means of molecular adjuvants is becoming a new tool for vaccine improvement. Many reports, several of which are analyzed in this work, demonstrate that this approach can be potentially useful for different types of vaccines. However, the vast majority of studies on the inhibition of Tregs during vaccination have been performed with antitumor vaccines. Very few studies have been conducted with vaccines targeting infectious pathogens. Accordingly, more studies need to be conducted to evaluate the utility of Treg manipulation for anti-infectious disease approaches, and these approaches should be tailored on a case by case basis. One question that remains to be answered is the role of Tregs in the inducement of memory and/or effector immune responses, two important aspects for rational vaccine design [170] .
Another important aspect to consider is the type of vaccine being designed (prophylactic or therapeutic). The current attitude regarding the risks and benefits of vaccination favors safety over efficacy when a prophylactic vaccine is given to a healthy population, especially in children. However, for therapeutic vaccines, including for patients with cancer and chronic infectious diseases, a certain level of toxicity may be acceptable if the benefit of the vaccine is substantial [174] . Treg modulation could potentially cause immunological disturbances with dire consequences that cannot be predicted in advance. Therefore, any approach that targets Tregs for vaccination purposes should be confined to a short period, thus guaranteeing the necessary regulatory function to avoid long-term deleterious effects, including autoimmune reactions [15, 175] . In this way, differences in Tregs patterns between rodents and humans must be carefully analyzed to extrapolate experimental results from laboratory animals to humans (Fig. 3) .
Ultimately, the success of the new generation of molecular adjuvants targeting Tregs will depend on their ability to achieve potent but controlled immune responses. Subsequent studies should be aimed at achieving inhibition by means of antigen-specific Treg modulation. Thus, a deep understanding of Treg biology as part of the pathogenic mechanisms of disease is critical to support the increasing demand for potent and safe vaccines in the future.
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